True Wealth Design’s Coherus Oncology CHRS Stock Holding History

True Wealth Design’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$821	Buy	586 +246	+72%	+$402	﹤0.01%	2054
2026 Q1	$575	Buy	340 +44	+15%	+$78	﹤0.01%	2001
2025 Q4	$421	Buy	296 +76	+35%	+$111	﹤0.01%	2006
2025 Q3	$361	Sell	220 -566	-72%	-$630	﹤0.01%	2113
2025 Q2	$575	Sell	786 -2,812	-78%	-$2.43K	﹤0.01%	1690
2025 Q1	$2.9K	Sell	3,598 -699	-16%	-$804	﹤0.01%	876
2024 Q4	$5.93K	Buy	4,297 +1,728	+67%	+$1.94K	﹤0.01%	505
2024 Q3	$2.67K	Buy	+2,569	New	+$3.52K	﹤0.01%	708

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

True Wealth Design's CHRS Position: Q2 2026 in Review

True Wealth Design increased its Coherus Oncology (CHRS) stake by 72% in Q2 2026, buying an estimated $402 and bringing the position to 586 shares worth $821. The position accounts for ﹤0.01% of the portfolio, ranked #2054.

True Wealth Design first reported a position in CHRS in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.93K in Q4 2024. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

True Wealth Design held 586 shares of Coherus Oncology worth $821 as of Q2 2026.
True Wealth Design bought 246 Coherus Oncology shares in Q2 2026, an estimated $402.
Coherus Oncology made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2054 holding.
True Wealth Design first reported a position in Coherus Oncology in Q3 2024 and has held it in 8 quarters since.
True Wealth Design's Coherus Oncology position peaked at $5.93K in Q4 2024.
147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.